2021年1月15日

Intellasia東亞新聞15 - 1月- 2021年Intellasia |美通社亞洲| 9點是東京,1月15日,2021年美國免疫力,從有限公司有限公司(首席執行官Naozumi Harada博士米氏,日本),專門研究nanoparticle-based癌症免疫療法的藥物發現生物技術(nano-immunotherapies),已經進入聯合研究協議與Xyphos生物科學2020年12月,Inc .(美國加州)的子公司阿斯特拉製藥有限公司(日本東京)。聯合免疫標誌。聯合免疫建立商業化的結果長期合作工程的研究生院,京都大學和醫學院的畢業生,三重大學和從事各種活動從基礎研究到臨床應用的下一代nano-immunotherapies。利用公司的獨特的納米藥物對免疫係統和敵意的理解癌症的腫瘤免疫微環境(所謂的“冷腫瘤”),這與Xyphos共同研究項目旨在追求創造有效的下一代nano-immunotherapies目前棘手的癌症的治療並不是有效的。評論這個聯合研究Naozumi Harada曼聯的首席執行官免疫力,抗癌藥物的發展有限公司和癌症免疫療法利用納米技術正成為最熱門的領域之一腫瘤學領域的。之間的協同我們的專有技術和Xyphos nano-immunotherapy癌症免疫治療技術強烈預期導致下一代nano-immunotherapies的快速發現與臨床療效高。關於Xyphos生物科學公司,一家阿斯特拉公司。Xyphos生物科學公司,位於南舊金山,加州是一個全資子公司的阿斯特拉ACCELTM技術,汽車的技術平台(嵌合抗原受體)免疫細胞療法。ACCELTM技術是基於融合等receptor-expressing免疫細胞自然殺傷(NK)細胞和T細胞(convertibleCAR®細胞)識別腫瘤抗原的抗體,攻擊的目標。的技術是基於政府antibody-ligand融合蛋白(MicAbody),這是一個融合抗體和配體蛋白質。 By replacing or using multiple MicAbodies according to the characteristics of the cancer cells to be attacked, convertibleCAR® cells can recognize different cancer antigens or multiple cancer antigens and attack various cancer cells. Xyphos Biosciences was launched in 2017, and the Company was acquired by Astellas Pharma in December of 2019. For more information about the Company, please visit www.xyphosinc.com . About Astellas Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at https://www.astellas.com/en . About United Immunity, Inc. United Immunity is a unique biotech that aims to commercialize nano-immunotherapy that combines nanotechnology and immunotherapy against cancer and viruses. The company is working on the commercialization of new drugs in the following disease areas. Cancer: The majority of cancers are refractory to standard therapies and even the latest cancer immunotherapies, and this is an important global issue in the field of oncology. Our proprietary nano-immunotherapy technology, including the T-ignite® series, activates the immune system within the tumor tissue and converts treatment-resistant cold tumor into sensitive hot tumor. New Coronavirus Infections (COVID-19): The pandemic caused by the new coronavirus has become a global issue with loss of lives, medical collapse crisis, and economic recession. The company will contribute to ending this pandemic by rapidly developing a highly effective, safe, and easily distributable next generation vaccine using our nanotechnology. Related Links :